BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hangzhou Highlightll Pharmaceutical readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Hangzhou Highlightll Pharmaceutic
 al's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07629778-1383@assetmemo.bio
DTSTAMP:20261121T005927Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:HL-300: Phase 1/2 readout est. (NCT07629778)
DESCRIPTION:HL-300\, phase 1/2\, Atopic Dermatitis.\nStudy: HL-300 Ointment
  in Patients With Mild-to-Moderate Atopic Dermatitis\nEstimated primary co
 mpletion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/hl-300#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07629778
URL:https://assetmemo.bio/drug/hl-300#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976268-1604@assetmemo.bio
DTSTAMP:20261121T005927Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:BHV-8000: Phase 2/3 readout est. (NCT06976268)
DESCRIPTION:BHV-8000\, phase 2/3\, Parkinson's Disease.\nStudy: A Study to 
 Determine if BHV-8000 is Effective\, Safe and Tolerable as a Treatment for
  Adults Living With Early Parkinson's Disease\nEstimated primary completio
 n: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bhv-8
 000#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06976268
URL:https://assetmemo.bio/drug/bhv-8000#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
